ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / MD
BKD (32) SGRY (66) ARDT (69) NHC (72) ⌘ Pro Terminal →

Pediatrix Medical Group Inc. (MD) — RQD Stock Rating Cockpit

$30.71 +2.99% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $30.95

Pediatrix Medical Group Inc. (MD) earns a Roarable Rating of B+ (Buy) with 77/100 RQD Confidence. High-quality cash engine (steady margins, 34% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B+ • BUY Cap $2.33B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Pediatrix Medical Group Inc. (NYSE: MD) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 77/100 at a spot price of $30.71 (+2.99% 1D, market cap $2.33B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 17/20. Across 1015 tracked Health Care issuers, MD ranks #26 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MD compare to BKD and SGRY in the Health Care sector?
▼

Within the Health Care sector (Hospital/Nursing Management), MD carries a Roarable B+ (77/100 RQD), trailing P/E of 14.3x, gross margin of —, and ROIC of 33.6%. By comparison, BKD (Brookdale Senior Living Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC 0.3%, cap $2.48B) and SGRY (Surgery Partners Inc.) posts a C+ grade (66/100 RQD, P/E N/A, ROIC 9.9%, cap $3.04B). Among the 5-stock peer group, ARDT leads on earnings multiple (12.8x) while MD leads on capital efficiency (33.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MD?
▼

Per MD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000893949), Pediatrix Medical Group Inc. generated $584.7M in revenue (+203.9% YoY), $165.4M in net income, and $271.1M in free cash flow against $2.25B in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $30.95 (+0.78%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 46.4% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 77/100 (B+) historically ranked in the Top 10% of excess returns over the next 90 days (+7.8% avg 90D alpha vs SPY • 70.3% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B+
025507510077
2-of-3 Quant Analysts Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw A- · Rk C+
Cash (16)Whales (17)SEC (13)Macro (14)CEO (17)
Each axis scored 0–20
12M PRICE TARGET CONE+8.6% Base Target
$39 Bull$33 Base$25 Bear
📬 FREE MD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MD)Realized 20D OHLCV Swing Band: ±6.3%
Deterministic 5-Pillar Attribution (77/100 Composite)
🔍 WHY MD SCORES 77/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+17/20 pts (22% of score)

20D Institutional Volume Accumulation (±6.3% realized swing band)

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (22% of score)

SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)

▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk13/20 pts (-7 pt drag)

Balance-sheet & 10-K footnote risk deducts 7 pts from forensic ceiling

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
69
Grade B-$26.61+5.5% Next Q
Q2 (-2Q)
72
Grade B$28.08+2.7% Next Q
Q3 (-1Q)
74
Grade B+$28.84+6.5% Next Q
Current
77
Grade B+$30.71+7.8% Hist 90D α
Trajectory: B- (69) → B+ (77)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the MD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 77/100 (B+) score, MD faces multiple-compression risk if 14.3x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($27.05) or 200D SMA ($23.94) invalidates the momentum regime and cuts Target Base ($33.34) toward Bear Floor ($25.18).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 77%NO 23%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
67.330 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCORESOLID CORE (5–6)
6 / 99-Pt Accounting
52-WEEK LASER RANGE99% OF RANGE
L: $17$30.71H: $31
1. Money & Cash Health● HEALTHY
Are profits real cash in the bank?

Real cash coming in backs up reported profits (steady margins and healthy balance-sheet cushion).

Factor Grade: B+RQD 16 / 20
2. Big Money & Insiders● BUYING
Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: A-RQD 34 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: C+RQD 27 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

2-of-3 Quant Analysts Bullish on MD

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (80)

33.6% ROIC with 42.0% gross margin and 11.43% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (65)

Altman-Z 4.20 and Piotroski 6/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BULLISH (80)

34/40 institutional & smart-money positioning score with 14/20 macro alignment.

Bull Case: Why Buyers Like MD
  • ✓Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.
  • ✓Big institutional funds and options desks are actively positioning on the bullish side.
  • ✓Company leadership has skin in the game with net positive insider conviction.
Bear Case: What Could Go Wrong
  • !Broader market pullbacks can still drag down strong stocks in the short run.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (MD Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
MD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +37.04%▲ RESISTANCE BREAKOUT
2026-11-03O $29.18H $30.71L $29.18C $30.71VOL 1.11M
RES: $30.45SUP: $24.79SMA50: $27.05SMA200: $23.94
$31.50$28.24$24.97$21.71$18.45RES $30.45SUP $24.79$30.712026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MD Butterfly Map → + Track MD →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
6.2%/yr Implied 5Y Growth

vs. +203.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MD)

Health Care Rank #26 of 1015 ⚔️ BKD vs MD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MD vs. BKD, SGRY, ARDT, NHC)

Industry: Hospital/Nursing Management (14 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Pediatrix Medical Group Inc. (MD) ranks #26 by composite RQD confidence (77/100, grade B+) and #228 by equity capitalization ($2.33B). Within this direct 5-issuer industry benchmark cohort, ARDT leads on earnings valuation at 12.8x trailing P/E, while MD leads on capital efficiency and profitability with 33.6% ROIC and — gross margin. MD currently leads its immediate peer cohort in composite quantitative strength at 77/100 (B+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MD ACTIVE
Pediatrix Medical Group Inc.
B+ 77/100 14.3x — 33.6% +2.99% $2.33B Benchmark Subject
BKD
Brookdale Senior Living Inc.
E 32/100 — 26.2% 0.3% +0.48% $2.48B /bkd-vs-md →
SGRY
Surgery Partners Inc.
C+ 66/100 — — 9.9% -0.39% $3.04B /sgry-vs-md →
ARDT
Ardent Health Inc.
C+ 69/100 12.8x — 10.5% -2.49% $1.70B /ardt-vs-md →
NHC
National HealthCare Corporation
B 72/100 27.7x — 10.1% -1.96% $3.23B /nhc-vs-md →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000893949 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pediatrix Medical Group Inc. (MD) reported GAAP revenue of $584.7M (+203.9% vs. FY2024 revenue of $192.4M , and +2752.2% cumulative change since FY2023) , GAAP net income of $165.4M, operating cash flow of $271.1M, and free cash flow of $271.1M (+31.2% YoY). On the balance sheet, MD closed FY2025 with $2.25B in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $584.7M $165.4M $271.1M $271.1M $2.25B —
FY2024 (FY) 2024-12-31 $192.4M -$99.1M $206.6M $206.6M $2.15B —
FY2023 (FY) 2023-12-31 $20.5M -$60.4M $137.3M $137.3M — —

3. MD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Pediatrix Medical Group Inc. (NYSE: MD) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 77/100 at a spot price of $30.71 (+2.99% 1D, market cap $2.33B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 17/20. Across 1015 tracked Health Care issuers, MD ranks #26 in composite RQD confidence.

How does MD compare to BKD and SGRY in the Health Care sector?

Within the Health Care sector (Hospital/Nursing Management), MD carries a Roarable B+ (77/100 RQD), trailing P/E of 14.3x, gross margin of —, and ROIC of 33.6%. By comparison, BKD (Brookdale Senior Living Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC 0.3%, cap $2.48B) and SGRY (Surgery Partners Inc.) posts a C+ grade (66/100 RQD, P/E N/A, ROIC 9.9%, cap $3.04B). Among the 5-stock peer group, ARDT leads on earnings multiple (12.8x) while MD leads on capital efficiency (33.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MD?

Per MD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000893949), Pediatrix Medical Group Inc. generated $584.7M in revenue (+203.9% YoY), $165.4M in net income, and $271.1M in free cash flow against $2.25B in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MD trading relative to its 50-day, 200-day, and 52-week technical levels?

MD last traded at $30.71 (+2.99% on volume of 1,171,101 shares), positioning the stock +13.53% above its 50-day simple moving average ($27.05) and +28.28% above its 200-day simple moving average ($23.94). Across its 52-week range of $17.23 to $30.55, MD sits at the 100.0% percentile with a 14-day RSI of 67.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.3% ($28.78 to $32.64).

Direct Sub-Reports: MD RQD Cockpit MD 12M Forecast MD Earnings & Move MD Dividends & DRIP MD Insiders & 13F MD Whale Options MD Profit Sankey MD News & Why
ROARABLE RATING BRIEF • RQD 77/100 (B+) ✓ SEC XBRL & RQD VERIFIED

MD — Pediatrix Medical Group Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Pediatrix Medical Group Inc. (MD) earns a live Roarable RQD composite score of 77/100, corresponding to a B+ letter grade (Roarable Buy) at a spot price of $30.71 (+2.99% 1D, market capitalization $2.33B).

  • Fundamental Cash Engine (16/20): Anchored by return on invested capital (ROIC) of 33.6%, gross margin of —, operating margin of —, and free cash flow yield of 11.43%.
  • Whale 13F & Options Flow (17/20) + Insider Conviction (17/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (14/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 6/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Pediatrix Medical Group Inc. Is a NYSE-listed issuer in the Health Care sector, operating in the Hospital/Nursing Management industry. The profile identifies the business as a hospital and nursing management operator. Revenue is reported as — in each period of the financials, so the revenue-generation mechanics cannot be described from this dataset.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Pediatrix Medical Group Inc. (MD) reported $584.7M in annual revenue (up from $192.4M in FY2024, +203.9% YoY) and $165.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($20.5M revenue, -$60.4M net income) through FY2025, MD scaled operating cash flow to $271.1M and free cash flow to $271.1M, backed by $2.25B in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (B+ • RQD 77/100): Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Big institutional funds and options desks are actively positioning on the bullish side. With Fundamental Cash Engine at 16/20 and Institutional Whale Flow at 17/20, sustained execution supports upside toward the upper end of the $17.23 – $30.55 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 14.3x trailing P/E and 9.6x EV/EBITDA against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Second-order bottlenecks cannot be identified from this dataset. An investor should note that the absence of mapped links is itself a limitation rather than evidence of an absence of dependencies.

  • Key Question #1: Can MD sustain or expand its — operating margin and 33.6% ROIC against Hospital/Nursing Management peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $584.7M and free cash flow of $271.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is MD's 13.3x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

MD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Pediatrix Medical Group Inc. (MD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MD Bull vs. Bear Conversation Board — What's Your Call at $30.71?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on MD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $38.47 (+29.0%)
📌 Pinned Debate

Per the RQD rating, 33.6% ROIC and an 11.43% FCF yield at a 13.3 forward P/E indicate strong cash generation at a moderate valuation.

The street is overcomplicating Pediatrix Medical Group Inc. (MD). Per the RQD rating, 33.6% ROIC and an 11.43% FCF yield at a 13.3 forward P/E indicate strong cash generation at a moderate valuation.. With an RQD score of 77/100 (B+) and Forensic Balance Sheet at 13/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $32.21.

RetailWhale_TX 🐂 BULL

@BearTrap_Alert Shorting a 17/20 institutional whale-flow stock at $29.82 is dangerous when funds are rotating into Health Care.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $25.05 (-16.0%)
Spot @ $29.82

Revenue is reported as $0.0M in every period and net income fell to $47 million per one headline, leaving the top line and earnings qua

Careful chasing MD at $29.82. Revenue is reported as $0.0M in every period and net income fell to $47 million per one headline, leaving the top line and earnings quality unverified.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $25.05 on multiple compression.

LIVE TAPE